Scilex (SCLX) News Today $4.73 -0.06 (-1.25%) As of 01:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCLX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review JournalJune 5, 2025 | globenewswire.comScilex Holding Stock Price HistoryJune 1, 2025 | investing.comScilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FLMay 16, 2025 | globenewswire.comScilex adjusts director compensation post-stock splitMay 13, 2025 | investing.comScilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.May 1, 2025 | globenewswire.comScilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price RuleApril 30, 2025 | globenewswire.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025April 22, 2025 | globenewswire.comScilex (NASDAQ:SCLX) Reaches New 1-Year Low - Should You Sell?Scilex (NASDAQ:SCLX) Sets New 52-Week Low - Here's WhyApril 19, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Trading Down 12.2% - Here's What HappenedScilex (NASDAQ:SCLX) Stock Price Down 12.2% - Should You Sell?April 18, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Sees Large Volume Increase - Here's WhyScilex (NASDAQ:SCLX) Sees Large Volume Increase - What's Next?April 17, 2025 | marketbeat.comScilex Gets Orphan Drug Designation for Its Version of ColchicineApril 17, 2025 | marketwatch.comScilex treatment of pericarditis granted FDA orphan designationApril 17, 2025 | markets.businessinsider.comScilex confirms FDA awards orphan drug designation for colchicineApril 17, 2025 | markets.businessinsider.comScilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of PericarditisApril 16, 2025 | globenewswire.comScilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in CanadaApril 15, 2025 | globenewswire.comScilex announces 1-for-35 reverse stock splitApril 12, 2025 | markets.businessinsider.comD. Boral Capital Downgrades Scilex Holding (SCLX)April 12, 2025 | msn.comScilex downgraded to Hold from Buy at D. Boral CapitalApril 11, 2025 | msn.comScilex Holding Company Announces 1-for-35 Reverse Stock SplitApril 11, 2025 | globenewswire.comD. Boral Capital Lowers Scilex (NASDAQ:SCLX) Price Target to $18.00D. Boral Capital decreased their price target on Scilex from $22.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday.April 4, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Stock Price Up 1.8% - Here's What HappenedScilex (NASDAQ:SCLX) Shares Up 1.8% - Still a Buy?March 27, 2025 | marketbeat.comScilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against AvevaMarch 26, 2025 | globenewswire.comScilex Holding Company Announces Change of Record Date for Preferred Stock DividendMarch 12, 2025 | nasdaq.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025March 10, 2025 | globenewswire.comScilex (SCLX) Projected to Post Earnings on MondayScilex (NASDAQ:SCLX) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comShort Interest in Scilex Holding (NASDAQ:SCLX) Expands By 40.6%Scilex Holding (NASDAQ:SCLX - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 6,100,000 shares, an increase of 40.6% from the January 31st total of 4,340,000 shares. Approximately 3.4% of the company's stock are sold short. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is currently 4.3 days.March 4, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Receives Buy Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $22.00 target price on shares of Scilex in a research report on Friday.March 1, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Stock Price Down 1.7% - Time to Sell?Scilex (NASDAQ:SCLX) Shares Down 1.7% - What's Next?February 22, 2025 | marketbeat.comScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025January 31, 2025 | globenewswire.comScilex (NASDAQ:SCLX) Coverage Initiated at D. Boral CapitalD. Boral Capital began coverage on Scilex in a research report on Monday. They issued a "buy" rating and a $22.00 price target for the company.January 28, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Coverage Initiated by Analysts at D. Boral CapitalD. Boral Capital initiated coverage on Scilex in a research note on Monday. They issued a "buy" rating and a $22.00 price target on the stock.January 27, 2025 | marketbeat.comScilex regains compliance with Nasdaq listing rulesJanuary 21, 2025 | markets.businessinsider.comScilex to file SNDA with FDA for ELYXYBJanuary 21, 2025 | markets.businessinsider.comSCLX Beats on Earnings as Product Line ExpandsJanuary 21, 2025 | msn.comScilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)January 21, 2025 | globenewswire.comScilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025January 21, 2025 | globenewswire.comScilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLCJanuary 21, 2025 | globenewswire.comScilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024January 21, 2025 | globenewswire.comScilex (NASDAQ:SCLX) Announces Earnings ResultsScilex (NASDAQ:SCLX - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter.January 17, 2025 | marketbeat.comScilex amends license agreement with Romeg TherapeuticsJanuary 17, 2025 | markets.businessinsider.comScilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in AdultsJanuary 16, 2025 | globenewswire.comScilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5%January 13, 2025 | markets.businessinsider.comScilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% PatchJanuary 13, 2025 | markets.businessinsider.comWall Street Futures Gain Pre-Bell Tuesday, Pointing to Higher Open for 2024's Last SessionDecember 31, 2024 | msn.comScilex announces change in record date for dividend of preferred stockDecember 30, 2024 | markets.businessinsider.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025December 30, 2024 | globenewswire.comScilex Holding (NASDAQ:SCLX) Short Interest Down 14.0% in DecemberScilex Holding (NASDAQ:SCLX - Get Free Report) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 5,280,000 shares, a decrease of 14.0% from the November 30th total of 6,140,000 shares. Approximately 3.3% of the shares of the stock are short sold. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is presently 2.6 days.December 30, 2024 | marketbeat.comWall Street Futures Inch Higher Ahead of Tuesday's Shortened Trading HoursDecember 24, 2024 | msn.comScilex Holding (NASDAQ:SCLX) Insider Acquires $13,800.00 in StockDecember 19, 2024 | insidertrades.comScilex Holding Company Announces Early Repayment of $13.2 Million Under Oramed NoteDecember 18, 2024 | nasdaq.com Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLX Media Mentions By Week SCLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SCLX News Sentiment▼1.890.90▲Average Medical News Sentiment SCLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SCLX Articles This Week▼12▲SCLX Articles Average Week Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACTU News ENGN News LRMR News DERM News TLSA News SGMT News ALMS News EDIT News ACRS News ENTA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SCLX) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
